Actively Recruiting

Phase 1
Phase 2
All Genders
NCT04159103

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Led by ModernaTX, Inc. · Updated on 2026-01-22

77

Participants Needed

35

Research Sites

332 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This 3-part, Phase 1/2 study is designed to characterize the safety, tolerability, and pharmacological activity (as assessed by biomarker measurements) and to determine the selected dose of mRNA-3927 in participants with genetically confirmed propionic acidemia (PA). After establishing a dose with an acceptable safety and pharmacodynamic (PD) response for participants ≥1 year of age in Part 1, participants will be enrolled in Part 2 (which will serve as the pivotal study) to allow for determination of the efficacy, safety, and PD of mRNA-3927. Part 3 will evaluate the safety, efficacy and PD response of mRNA-3927 in infants (\<1 year of age).

CONDITIONS

Official Title

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants 8 years or older at consent if among the first 2 in Part 1
  • Participants 1 year or older at consent if enrolled after the first 2 in Part 1
  • Confirmed diagnosis of propionic acidemia by molecular genetic testing
  • For Part 2: at least one documented metabolic decompensation event in the 12 months before consent
  • Infants under 1 year identified by newborn screening or suspected PA with a sibling diagnosed with PA
  • For NICU infants: born at or after 37 weeks gestational age without interfering conditions
  • Body weight of at least 3 kilograms at screening
  • At least one documented PA-related event prior to screening, including metabolic deterioration signs or laboratory abnormalities
Not Eligible

You will not qualify if you...

  • Clinically significant laboratory abnormalities that could limit study participation
  • Estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² for those on chronic dialysis
  • History or planned organ transplantation during study participation
  • Corrected QT interval (QTc) over 480 milliseconds
  • Grade 3 or 4 heart failure by pediatric or adult classification
  • Pregnant or breastfeeding
  • Other significant medical conditions that could affect safety or study results

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 35 locations

1

UCSD Altman Clinical and Transalational Research Institute Building

Los Angeles, California, United States, 90027

Not Yet Recruiting

2

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States, 90095

Actively Recruiting

3

Lucile Packard Children's Hospital Stanford

Stanford, California, United States, 94304

Actively Recruiting

4

Nicklaus Children's Hospital

Miami, Florida, United States, 33155

Not Yet Recruiting

5

University of South Florida - 12901 Bruce B Downs

Tampa, Florida, United States, 33606-3603

Not Yet Recruiting

6

Ann and Robert H Lurie Childrens Hospital of Chicago

Chicago, Illinois, United States, 60611

Actively Recruiting

7

Johns Hopkins Hospital, Adult Outpatient Clinical Research Unit

Baltimore, Maryland, United States, 21287

Completed

8

Boston Children's Hospital

Boston, Massachusetts, United States, 02115

Completed

9

University of Michigan Hospitals

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

10

Icahn School of Medicine at Mount Sinai - Clinical Research Unit

New York, New York, United States, 10029

Actively Recruiting

11

Duke University Medical System (Duke Health)

Durham, North Carolina, United States, 27710

Actively Recruiting

12

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Completed

13

University Hospitals Cleveland Medical Center - 11100 Euclid Ave

Cleveland, Ohio, United States, 44106-2624

Active, Not Recruiting

14

Children's Hospital of Philadelphia (CHOP)

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

15

Texas Children's Hospital

Houston, Texas, United States, 77030

Actively Recruiting

16

Stollery Children's Hospital University of Alberta

Edmonton, Alberta, Canada, T6G 2R7

Actively Recruiting

17

Hospital For Sick Children

Toronto, Ontario, Canada, M5G 1X8

Actively Recruiting

18

CHU de Marseille - Hôpital de la Timone

Marseille, France, 13005

Active, Not Recruiting

19

Hôpital Necker - Enfants Malades

Paris, France, 75019

Actively Recruiting

20

Fujita Health University Hospital

Toyoake-shi, Aichi-ken, Japan, 470-1192

Actively Recruiting

21

Tohoku University Hospital

Sendai, Miyagi, Japan, 980-8574

Actively Recruiting

22

National Center for Child Health and Development

Tokyo, Japan, 113-8519

Active, Not Recruiting

23

Erasmus MC

Rotterdam, South Holland, Netherlands, 3015 GD

Actively Recruiting

24

Universitair Medisch Centrum Utrecht - PPDS

Utrecht, Netherlands, 3584 CX

Active, Not Recruiting

25

King Faisal Specialist Hospital & Research Center - Riyadh

Riyadh, Ar Riya, Saudi Arabia, 11211

Active, Not Recruiting

26

King Fahad Medical City

Riyadh, Ar Riya, Saudi Arabia, 11564

Not Yet Recruiting

27

King Abdullah Children's Specialist Hospital

Riyadh, Ar Riya, Saudi Arabia, 14611

Not Yet Recruiting

28

Hospital Sant Joan de Deu - PIN

Esplugues de Llobregat, Barcelona, Spain, 8950

Active, Not Recruiting

29

Hospital Universitario Cruces

Barakaldo, Biscay, Spain, 48903

Actively Recruiting

30

Hospital Universitario 12 de Octubre

Madrid, Spain, 28041

Actively Recruiting

31

Hospital Universitario Virgen del Rocio - PPDS

Seville, Spain, 41013

Active, Not Recruiting

32

University Hospital Birmingham NHS Foundation Trust

Birmingham, United Kingdom, B15 2TH

Actively Recruiting

33

Birmingham Children's Hospital

Birmingham, United Kingdom, B4 6NH

Completed

34

Great Ormond Street Hospital for Children NHS Foundation Trust

London, United Kingdom, WC1N 3JH

Actively Recruiting

35

Willink Biochemical Genetics Unit - PPDS

Manchester, United Kingdom, M13 9WL

Actively Recruiting

Loading map...

Research Team

M

Moderna WeCare Team

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here